RGNCM
ALXN

R.G. Niederhoffer Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

R.G. Niederhoffer Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,600
Closed -$303K – 30
2013
Q3 		$303K Buy
+2,600
New +$285K 1.87% 24

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

R.G. Niederhoffer Capital Management's ALXN Position: Q4 2013 in Review

R.G. Niederhoffer Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2013, closing a stake of 2,600 shares — an estimated $303K sold.

R.G. Niederhoffer Capital Management first reported a position in ALXN in Q3 2013 and held it in 1 quarter. The position peaked at $303K in Q3 2013. 463 funds tracked by Wall St. Rank hold ALXN as of Q4 2013.

  • R.G. Niederhoffer Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • R.G. Niederhoffer Capital Management sold 2,600 Alexion Pharmaceuticals shares in Q4 2013, an estimated $303K.
  • R.G. Niederhoffer Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • R.G. Niederhoffer Capital Management's Alexion Pharmaceuticals position peaked at $303K in Q3 2013.
  • 463 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2013.

Based on R.G. Niederhoffer Capital Management's 13F filing for Q4 2013.